Sign In
Buy RDY
$13.02
-0.0100 (-0.0767%)
At Close: Jun 03, 2026
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
07:40am, Friday, 25'th Oct 2024
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanAssociationfortheAdvancementofScience--Dr. Reddy's has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Su
Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
09:47am, Monday, 14'th Oct 2024
PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's launches comprehensive menopause support program and training for employees during menopause awareness month.
BENGALURU, India & HYDERABAD, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
10:41am, Friday, 20'th Sep 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
12:00pm, Wednesday, 21'st Aug 2024
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
01:33am, Tuesday, 13'th Aug 2024
Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as
Dr. Reddy's Laboratories: India 'will be our number one market'
08:25pm, Tuesday, 30'th Jul 2024
Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
11:10am, Monday, 29'th Jul 2024
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
Dr. Reddy's Q1FY25 Financial Results
09:51am, Saturday, 27'th Jul 2024
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
11:25am, Thursday, 27'th Jun 2024
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
11:26am, Wednesday, 26'th Jun 2024
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Acquisition--Dr. Reddy's to acquire Nicotinell and related portfolio in significant step towards building global consumer healthcare business.
HYDERABAD, India--(BUSINESS WIRE)-- #Aurigene--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
09:53am, Tuesday, 28'th May 2024
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
01:21pm, Wednesday, 22'nd May 2024
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
